Pharma's AI ROI gap isn't strategy or tech; it's the missing workforce qualification step every other regulated capability requires.

Pharma's AI ROI Problem Isn't a Tech Problem but a Qualification Problem

In this episode, we discuss AI drug discovery hype, agent security risks, and why pharma's AI workforce bets remain unproven.

Manufacturing Intelligence: Sizing Up Pharma's Biggest AI Deals, Part Two

Three regulatory actions are converging to move biologics, gene therapy, and the ATMP platform forward quickly

Regulatory Actions Impacting Biologics

Modernizing infrastructures, record drug approvals, and harmonization were all positive regulatory advancements in July 2026.

Regulatory Roundup—July 2026

This episode of Pharma Fundamentals provides an introduction to hold times in biopharmaceutical manufacturing and how they differ from hold times in small-molecule drug manufacturing.

Pharma Fundamentals: An Introduction to Hold Times in Biopharmaceuticals

The use of artificial intelligence is facing harder questions of governance and data quality

PharmTech Weekly Roundup—July 17, 2026

Three regulatory actions are converging to move biologics, gene therapy, and the ATMP platform forward quickly, say Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, technical, Parexel.

How evolving regulatory expectations are reshaping pharma development and manufacturing.

Drug Digest April 2026

Alfred Rumondor, PhD, CMC Support for Due Diligence for External Assets at AbbVie.

Swita Singh, PhD, Senior Director and Strategic CMC Leader at Bristol Myers Squibb. Dr. Swita Singh holds a Ph.D. in Pharmaceutical Sciences and brings over fifteen years of distinguished expertise in Chemistry, Manufacturing, and Controls (CMC) development across biologics, antibody drug conjugates, and small molecules, with a proven record of driving strategic initiatives, optimizing complex business processes, and leading cross-functional teams to achieve regulatory and operational excellence. Recognized for delivering innovative, end-to-end CMC strategies that guide programs from early clinical development through successful commercialization, she has cultivated talent and shaped organizational culture throughout her career, while her commitment to stakeholder communication and cross-functional collaboration has consistently advanced program objectives across the industry. Having built her expertise at Pfizer and Eli Lilly and Company, Dr. Singh currently serves at Bristol Myers Squibb (BMS), where she continues to lead CMC strategy in support of transformative therapeutic development.

AAPS PharmSci 360: CMC Strategies, Part 1 

 spoke with Alfred Rumondor, PhD, CMC due diligence for external assets at AbbVie, and Swita Singh, PhD, Senior Director and Strategic CMC Leader at Bristol Myers Squibb, to learn more about their upcoming panel discussion, Navigating CMC Strategy in the Current Landscape, at 

, which is being held from October 25-28 in New Orleans. In part 1 of this 3-part interview, Rumondor and Singh discussed how chemistry, manufacturing, and controls (CMC) review practices are evolving and what that means for manufacturing strategy.

Singh identified the most consequential shift as a move from informal, reviewer-dependent flexibility to formal, risk-based flexibility applied consistently across the product life cycle. She pointed to Operation TrailBlazer and updated phase 1 CMC guidance as examples, stating they are reducing required manufacturing data pre-investigational new drug application (IND). Singh also pointed out that cell and gene therapy programs no longer need 3 independent process performance qualification batches and can flex specifications for small-batch production. AI-driven tools and emerging credibility frameworks are reinforcing this trend by helping generate cleaner data packages for faster, more consistent regulatory decisions.

Singh cautioned, however, that companies must build “risk justification muscle” rather than simply accepting flexibility at face value. Reduced requirements should be treated as deferral, not elimination, of data obligations; organizations need clear plans for when deferred data will be generated and which milestones trigger it. She emphasized investing early in comparability infrastructure, leveraging platform and prior-knowledge pathways, and engaging proactively with regulators.

Rumondor addressed the pressure to compress development timelines. He argued the real question isn’t whether compression is safe, but how to do it properly by working smarter rather than skipping steps. He cited premature form selection without adequate screening as a common shortcut that later may bring costly bridging and comparability studies, increasing both timeline and program risk. Compressed timelines are achievable, but only when teams rigorously plan the full development path upfront, according to Rumondor.

Alfred C. Rumondor, PhD, Director, Development Sciences Licensing and Acquisitions, AbbVie

, is Director, Development Sciences Licensing and Acquisitions, at AbbVie.

Swita Singh, PhD, Senior Director and Strategic CMC Leader at Bristol Myers Squibb

holds a Ph.D. in Pharmaceutical Sciences and brings over fifteen years of distinguished expertise in Chemistry, Manufacturing, and Controls (CMC) development across biologics, antibody drug conjugates, and small molecules, with a proven record of driving strategic initiatives, optimizing complex business processes, and leading cross-functional teams to achieve regulatory and operational excellence. Recognized for delivering innovative, end-to-end CMC strategies that guide programs from early clinical development through successful commercialization, she has cultivated talent and shaped organizational culture throughout her career, while her commitment to stakeholder communication and cross-functional collaboration has consistently advanced program objectives across the industry. Having built her expertise at Pfizer and Eli Lilly and Company, Dr. Singh currently serves at Bristol Myers Squibb (BMS), where she continues to lead CMC strategy in support of transformative therapeutic development.

Videos

In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discussed how CMC review practices are evolving and what that means for manufacturing strategy.

AAPS PharmSci 360: CMC Strategies, Part 1

Novartis makes a $3.2 Billion bet on a subcutaneous formulation platform.

Novartis has entered into an option and license agreement with Alteogen Inc. to develop and commercialize subcutaneous formulations of multiple Novartis products, using a recombinant human hyaluronidase enzyme called ALT-B4.

 The agreement gives Novartis a series of options to secure exclusive development and commercialization rights across several of its products, with Alteogen eligible to receive up to $3.2 Billion in option fees, development and commercial milestones, and royalties on net sales if every option is exercised and every milestone is met.

The deal is the fourth licensing agreement of this kind signed this year involving the same underlying enzyme platform, reflecting accelerating industry interest in converting intravenous biologics into subcutaneous formulations.

ALT-B4, also known as berahyaluronidase alfa, works by temporarily breaking down hyaluronan, a structural component of the extracellular matrix that normally limits how much fluid tissue can absorb at once.

 By depolymerizing hyaluronan at the injection site, the enzyme creates space for co-administered therapeutics to disperse and absorb more rapidly, allowing biologics that would typically require intravenous infusion to instead be delivered via subcutaneous injection. This class of enzyme has become a recognizable lever in biologics formulation over the past several years, since it addresses a persistent bottleneck: many large-molecule drugs, particularly monoclonal antibodies administered in high volumes, simply cannot be injected subcutaneously without a mechanism to help the tissue accommodate the dose.

What Are the Effects On Development and Manufacturing Teams?

Subcutaneous conversion programs reshape manufacturing and supply chain planning in ways that infusion-only products do not.

 Converting an intravenous product to subcutaneous delivery typically means redesigning fill-finish operations around prefilled syringes or autoinjectors rather than vials for infusion bags, adjusting formulation to support smaller injection volumes and higher concentrations, and revisiting stability and container-closure strategies. It also has commercial implications: subcutaneous formulations can reduce dependence on infusion center capacity, shorten administration time, and support at-home or self-administration models, all of which have become priorities as health systems look to manage infusion chair capacity and patient convenience simultaneously.

The scale of the agreement also signals how large pharmaceutical companies are approaching platform licensing for delivery technology.

 Rather than developing hyaluronidase or comparable enzymes internally, Novartis is opting to license access to an established platform with multiple options across its portfolio, a structure that lets the company evaluate applicability across different molecules and modalities before committing to full development on any single product.

Tae-Yon Chun, PhD, CEO, Alteogen, said in a press release,

 "Novartis is a world-leading pharmaceutical company at the forefront of the global healthcare industry and has evaluated the application of ALT-B4 across multiple modalities for subcutaneous formulation development. This agreement demonstrates the technological strength and commercial value of Alteogen's Hybrozyme platform."

The deal is another data point in a broader industry trend: platform-level licensing of delivery-enabling technologies, rather than one-off formulation partnerships, is becoming a more common route for large biopharmaceutical companies to diversify their subcutaneous pipeline without building proprietary enzyme technology from scratch.

 As more of these agreements are signed, development teams evaluating their own portfolios may increasingly weigh licensing established delivery platforms against investing in internal formulation science.

How Widespread Is this Shift Across the Industry?

Takeda's January 2026 agreement with Halozyme illustrates how far subcutaneous conversion has spread beyond oncology and rare disease.

 The deal grants Takeda exclusive access to Halozyme's hyaluronidase-based platform for vedolizumab, a therapy for ulcerative colitis and Crohn's disease with more than one million patient-years of exposure worldwide.

Robert Hollowell, head of global product and launch strategy, Takeda, said in a press release,

the collaboration would "offer greater flexibility in vedolizumab treatment, improve patient experience, and continue our focus on high-impact partnerships." With inflammatory bowel disease prevalence projected to exceed 10 million patients globally by 2032, the deal underscores sustained manufacturing demand for subcutaneous formats.

Alteogen Inc. Alteogen enters option and license agreement with Novartis for development and commercialization of Hybrozyme™-enabled subcutaneous products. PR Newswire. Press Release. September 2, 2026. 

https://www.prnewswire.com/news-releases/alteogen-enters-option-and-license-agreement-with-novartis-for-development-and-commercialization-of-hybrozyme-enabled-subcutaneous-products-302867513.html

Takeda Pharmaceutical Company Limited. Takeda announces global collaboration and license agreement with Halozyme to continue advancing vedolizumab with ENHANZE® drug-delivery technology. Takeda. Press Release. January 8, 2026. 

https://www.takeda.com/newsroom/newsreleases/2026/collaboration-and-license/

Articles

Novartis secured an option-and-license pact with Alteogen to enable subcutaneous delivery of multiple biologics using ALT-B4 (berahyaluronidase alfa), a recombinant human hyaluronidase that transiently depolymerizes hyaluronan to expand subcutaneous tissue capacity. Alteogen could receive up to $3.2 billion plus royalties if all options and milestones are achieved, underscoring rising demand for IV-to-SC lifecycle strategies. SC conversion reshapes fill-finish, device selection, formulation concentration, and stability planning, while potentially shifting care from infusion centers toward faster, home-based administration.

Novartis licenses Alteogen's ALT-B4 enzyme for subcutaneous drug conversion in a deal worth up to $3.2B, signaling formulation industry shift.

What Novartis's $3.2 Billion Enzyme Licensing Deal Means for Formulation

Robert Holt, PhD, Associate Director, Pharmaceutical Science, digiM Solution LLC

AAPS PharmSci 360: Microstructure Intelligence in Predictive Drug Development, Part 2

 keynote on predictive drug development, 

, associate director, Pharmaceutical Science, 

, provides examples of how microstructure intelligence compresses development timelines and strengthens regulatory filing, particularly for modern, complex products such as long acting therapies, oral peptides, and combination products.

Holt explains that microstructure data delivers value at each development stage, such as feasibility and screening, baseline scans for calculating critical quality attributes from minimal material, and informing early formulation decisions. During optimization, these tools link particle structure to dissolution and release performance, enabling in silico formulation tuning. At scale-up and tech transfer, platforms like digiM’s dissoLab and ivisLab run mechanistic simulations that stress-test manufacturing variations in minutes, reducing batch-failure risk and generating physics-based data packages for regulators.

Providing an example of the value of microstructure data, Holt shares a case study where a major pharma client saw a dissolution slowdown between lab-scale and good manufacturing practice (GMP) batches of spray-dried dispersions, despite conventional characterization (laser diffraction, mercury injection, BET, XRPD) showing the batches as comparable. X-ray microscopy combined with artificial intelligence (AI) image analysis revealed the real cause: the GMP batch had stronger aggregation from droplet merging, cutting particle surface area by 40% versus the lab batch's looser, electrostatic aggregation.

When asked about this technology’s future, Holt notes that digiM holds an FDA IDIQ contract for regulatory assessment and guideline development on complex drug products, and its work informed product-specific guidelines for minocycline microspheres and dexamethasone ophthalmic implants, with the FDA encouraging microstructural characterization for generics. Holt calls digiM “the first FDA-recognized microstructure platform for drug product development,” positioning the technology as an emerging pillar of quality-by-design and real-time release strategies, with new AI tools that generate 3D drug substance and product models from 2D images.

Looking ahead to AAPS PharmSci 360 in New Orleans, Holt says the keynote his company is presenting will explore imaging science, predictive science, and AI applications for emerging modalities, such as long-acting injectables, high-concentration biologics, and combination products, where microstructure intelligence is poised to address next-generation manufacturing challenges.

AAPS PharmSci 360 is happening in New Orleans from October 25-28, 2026.

Click the video above to watch the interview.

Robert Holt, PhD, associate director, Pharmaceutical Science, digiM Solution, discusses microstructure intelligence in more detail in part 2 of this preview of the company’s keynote presentation at AAPS PharmSci 360.

Medical award concept, winner cup on the desk | Image Credit: ©BillionPhotos.com -stock.adobe.com

The list of finalists for the 2026 CPHI Pharma Awards was announced on September 1, 2026,

 drawing from hundreds of submissions across 15 categories that track where drug development, manufacturing, and supply chain innovation are heading. Winners will be announced October 6 at a networking reception opening 

, which runs October 6–8. In a press release,

 Tara Dougal, CPHI event director at Informa Markets, called this year's field a marker of rising ambition across the industry, noting that finalists are “setting new standards across the board.”

API Development and Innovation finalists include Lonza's GlycoConnect dual-payload antibody-drug conjugate (ADC) technology; Cambrex's automated liquid-phase peptide synthesis platform; FUJIFILM Biotechnologies' ShunzymeX; and MODAG’s Combined neurodegeneration platform involving PD DETECT and Emrusolmin. These nominees showcase continued investment in complex modality manufacturing, particularly ADCs and peptides.

The Manufacturing Excellence category is a direct read on process innovation: Anemocyte's enzymatic messenger RNA (mRNA) manufacturing technology; IMA SpA's DOMINA tableting platform; Lyo Innovation's mass spectrometry-based lyophilization tracking; Bespak Bio's next-generation gene therapy manufacturing technology; and Touchlight's GMP-licensed cell-free DNA facility. Touchlight's platform also appears in the Sustainable Pharma Excellence category and its Cell-free Doggybone DNA (dbDNA) platform is listed in theInnovation Catalyst category, underscoring how its repurposed-infrastructure, smaller-footprint approach to cell-free DNA production is resonating across multiple judging lenses this year.

Digital Transformation finalists reflect the industry's push toward AI-enabled operations: Catalent's Qai Deviation Manager for enterprise quality workflows; Peerox’s MADDOX AI troubleshooting layer for packaging shopfloor operators; Evonik's self-driving labs; ForgeStop’s supply chain authentication platform; Adalvo’s digital transformation engine; and 4G Clinical’s digital clinical supply chain control system.

Supply Chain Excellence finalists include Cryoport Systems' ISO 21973 certification work in cold chain logistics; Almac Group's Adapt platform for ultra-rare gene therapy supply chains; LSPedia's OneScan traceability tool; Occam Systems data-driven strategy; and Adalvo’s supply chain planning efforts. These finalists are managing increasingly complex, temperature-sensitive, and serialized product flows.

Sustainability runs through several categories. In Sustainable Pharma Excellence, Nordic Bioproducts Group's AaltoCell microcrystalline cellulose, SCHOTT Pharma’s circular vial packaging, and SK Pharmteco's circular acetonitrile recovery framework each target resource efficiency in manufacturing inputs and packaging. In addition, Sunresin New Materials is featured for its polymer resin technology, Bloomage Biotechnology is nominated for its sodium chondroitin sulfate, and Celtic Renewables’ green chemistry is highlighted. The separate Sustainable Transformation Partnership category recognizes cross-industry collaboration, with Sartorius, AstraZeneca, Schneider Electric, and the Pharmaceutical Supply Chain Initiative all shortlisted for decarbonization and circular bioprocessing efforts.

Innovation in Drug Delivery, Devices and Packaging finalists include LTS Lohmann's AccuTip microneedle array platform and ForgeStop’s NFC- and secure-chip-based track-and-trace authentication, which is an area of growing regulatory and anti-counterfeiting relevance for manufacturers. Eco-Inject is nominated for its sustainable autoinjector; Palladio Group is nominated for its Smart Pill Pocket; and NVV Pharma is nominated for its earwax impaction medical device.

Beyond technology categories, the awards recognize individual and organizational leadership: CEO of the Year finalists include Adalvo's Anil Okay, SK Pharmteco's Joerg Ahlgrimm, and Biocon's Shreehas Tambe, among others, while Future Leader and Woman of the Year categories spotlight rising talent from organizations including Pfizer CentreOne, DFE Pharma, and Bristol Myers Squibb.

The 2026 awards are sponsored by IQVIA, the Industrial Technology Research Institute (ITRI), and the Taiwan Pharmaceutical Alliance. For manufacturing and contract development and manufacturing professionals attending CPHI Milan, the finalist list offers a useful preview of which technologies and companies are drawing industry-wide recognition this year. The awards ceremony itself is open to all registered attendees on the show's opening evening.

The full list of finalists is as follows:

 Combined neurodegeneration platform involving PD DETECT® and Emrusolmin

: GlycoConnect® dual-payload antibody-drug conjugate technology

: Automated liquid-phase peptide synthesis platform

 Digital Clinical Supply Chain Control for Complex Trials

: ForgeStop Connected Products Platform — NFC Authentication for Pharmaceutical Supply Chains

: Intelligence at Scale: How Adalvo Built an Enterprise-Grade Digital Transformation Engine at the Heart of a Specialist B2B Pharma Business

 AI-Driven Knowledge & Troubleshooting Layer Empowering Shopfloor Operators in Pharma Packaging

: Qai™ Deviation Manager: AI-Enabled Digital Quality Transformation at Enterprise Scale.

Innovation in Drug Delivery, Devices and Packaging

 ClearliQ Earwax: A Biomintetic Cerumenolytic Medical Device for Safe Self-Care of Earwax Impaction

: LTS AccuTip Microneedle Array Patch Platform

× EM Microelectronic - Secure Connected Packaging for Pharmaceutical Track-and-Trace and Authentication.

 Welcome Girl - A lifelong Noble Initiative” by Kepler Healthcare

Medical & Pharmaceutical Industry Development Agency of Uzbekistan

: Making medicines affordable in Uzbekistan: Reference Pricing, Digital Monitoring and Public Access

 Named patient import when every dose matters

 Hetronifly® (Serplulimab): Expanding Equitable Access to Immunotherapy Through Purpose Driven Collaboration.

 Innovative Mirabegron Modified-Release Formulation Platform for First-Generic Overactive Bladder Therapies

 NanoGlass™, a formulation platform for oral BCS IV and bRo5 drugs

 ASSEMBLA – A Scalable, Device Centric Assembly Platform Enabling End to End Medical Device Industrialisation 

 Optogenetic Platform Achieves Record-Breaking 21 g/L Antibody Titer

 StablevaX®: Catalysing an Ecosystem of Thermostable Medicines

 Cell-free Doggybone™ DNA (dbDNA™) platform

 AMCAP enzymatic mRNA manufacturing technology: Manufacturing technology

 Next-Generation Gene Therapy Manufacturing Technology

 World's First GMP-Licensed Cell-Free DNA Facility.

 Defining Pharmaceutical Supply Chain Excellence Through ISO 21973 Certification

 From Reactive to Resilient: How Adalvo Rebuilt Supply Chain Planning as a Strategic Advantage

 The Data-Driven Strategic Supply Chain Advantage

 Zero Margin for Error: Supply Chain Excellence in Ultra-Rare Gene Therapy with Almac Adapt™

 AaltoCell®: Transforming Pharmaceutical Manufacturing Through Sustainable High-Performance MCC

 Circular packaging – Delivery of pharmaceutical vials in circular packaging

 Transforming Solvent Sustainability in Pharmaceutical Manufacturing through a Data-Driven Framework and Circular Acetonitrile Recovery

 Uniform Functionalized Polymer Resin Technology: Redefining the Concept of Sustainability in Peptide Manufacturing

 World's First GMP-Licensed Cell-Free DNA Facility: Repurposed Infrastructure and Smaller Manufacturing Footprint.

 From Suppliers to End Users: Creating a Cross-Industry Partnership for Circular Bioprocessing

 Further Together: Partnering for Systemic Change

 Lead with Purpose, Decarbonize Faster - The PSCI Decarbonization Summit

 Pharma collaboration driving supply chain decarbonization

 A world-leading manufacturing research consortium spanning academic and industry partners

 Advancing First-in-Disease Topical Therapies Through Strategic Partnership: MedPharm and Palvella’s Co-Development of QTORIN™ Rapamycin from Concept to Commercial Readiness

 From At‑Risk to Accelerated: How Enzene Redefines Biologics Development

 More Than a Dossier: How Adalvo Builds True Partnerships on Shared Risk, Shared Reward, and Shared Mission

 Transforming of Complex Local Generics into Global Patient Access

 Zoliflodacin End-to-End Multiparty Partnership.

 ClearliQ: How a Dutch SME Disrupted Decades-Old Earwax Care with Biosolvent Science

 ODISEI - The Organoid-based Discovery Platform for Innovative Screening, Evaluation, and Identification

 Primogene – Cell-Free Enzymatic Biomanufacturing Platform

 VC-H1(Plant-based collagen alternative).

Dr Pauline van der Wijst-Janssen of DFE Pharma.

Maja Pedersen of FUJIFILM Biotechnologies

Finalists for the 2026 CPHI Pharma Awards span 15 categories, reflecting where drug development, manufacturing, digital operations, sustainability, and supply chains are concentrating investment. Winners will be announced October 6 at CPHI Milan. Shortlisted programs emphasize complex modalities (ADCs, peptides, mRNA, gene therapy), AI-enabled quality and shopfloor support, and increasingly stringent traceability and cold-chain standards. Sustainability recognition extends from circular packaging and solvent recovery to multi-company decarbonization partnerships. Leadership awards also highlight executive and emerging talent across major CDMOs and pharma organizations.

The finalists for the 2026 CPHI Pharma Awards span 15 categories including API development, digital transformation, manufacturing, supply chain, sustainability, and leadership, with winners revealed October 6 at CPHI Milan.

CPHI Milan Names 2026 Pharma Awards Finalists

AAPS PharmSci 360: Microstructure Intelligence in Predictive Drug Development, Part 1

, explains microstructure intelligence and how it can enhance how drug developers understand dosage forms.

According to Holt, “microstructure intelligence” is the science of understanding exactly where drug particles sit inside a dosage form, down to the microscopic level. Holt argues this spatial information is something traditional dissolution and content-uniformity testing simply can't capture. Two tablets can show identical drug content when tested, but if one has API concentrated at the surface and the other has it buried in the core, they will perform very differently. Conventional testing methods may miss this distinction, especially for extended-release products where uniformity matters most.

digiM employs multiple imaging modalities to understand the hidden architecture of a drug using an approach the company calls "correlative imaging." Based on the length scale specific to the given product and question, the approach will use electron microscopy, X-ray microscopy, polarized light microscopy and synchrotron CT. Its dissoLab and ivisLab tools then convert these real images into in silico microstructure models, applying physics-informed simulation kernels to predict dissolution and release behavior directly from the imaged sample. The company’s I2S tools use artificial intelligence (AI) for image segmentation, while a newer generative 

 lets scientists digitally alter traits like drug loading, particle size, porosity, and wall thickness to model how reformulated products would perform without manufacturing and testing new physical samples.

For manufacturers, microstructure intelligence may provide root-cause clarity: instead of just flagging that a batch dissolved faster or slower than expected, it can explain why. Holt notes the tools are browser-based and designed to be accessible regardless of company size, positioning this as a scalable diagnostic and formulation-optimization capability rather than a large-biopharma-only resource.

Click the video above to watch part 1 of the interview.

In part 1 of this 2-part preview of AAPS PharmSci 360’s keynote on predictive drug development, Robert Holt, PhD, associate director, Pharmaceutical Science, digiM Solution, explains microstructure intelligence and how it can enhance how drug developers understand the dosage form.

Regulatory Roundup—August 2026

In August 2026, a new FDA commissioner was nominated by the White House; there was a variety of novel drug approvals spanning oncology to narcolepsy; and parallel moves from the United Kingdom's MHRA and Europe's EDQM were made to modernize standards—all set against tightened manufacturing scrutiny on both sides of the Atlantic.

On August 19, 2026, the White House nominated 

 a physician with a Johns Hopkins doctorate and prior roles at the White House Domestic Policy Council and the America First Policy Institute, to fill the permanent FDA commissioner post left vacant since 

, after Acting Commissioner Kyle Diamantas reportedly turned the job down more than once. The nomination arrives as FDA works through a roughly 20% staffing reduction, and Senate confirmation is not guaranteed.

The White House announced what it called the 

largest annual drop in prescription drug prices in more than 60 years

 The administration credits Most Favored Nation pricing deals with 17 manufacturers covering roughly 86% of the branded market, alongside the TrumpRx platform (cited as generating $700 million in patient savings) and GLP-1 prices falling from over $1000 a month to as low as $149. The release reports prescription drug prices down 3.9% since the administration began and falling every month in 2026, with the Department of Veterans Affairs citing $10 billion in pharmaceutical savings for the fiscal year.

, spanning oncology, immunology, infectious disease, and rare genetic disorders.

 Several of these were approved in August.

In oncology, the FDA granted accelerated approval to Replimune's Tudriqev (vusolimogene oderparepvec-wtpg) in combination with nivolumab for 

 that has progressed on PD-1 therapy, a population where, as IGNYTE study investigator Michael Wong noted, patients “have few options after anti-PD-1 therapy and face high morbidity.”

 put the objective response rate at 24.2% among 91 evaluable patients, with a median duration of response of 14.1 months; confirmatory trials are required to maintain approval.

 as the first RAS-targeted therapy for metastatic pancreatic adenocarcinoma, arriving 6.5 months ahead of schedule after a 500-patient trial showed median overall survival of 13.2 months versus 6.7 months on chemotherapy. Center of Excellence Director, Angelo de Claro, called the results “unprecedented” for an area of high unmet need.

Bristol-Myers Squibb also picked up accelerated approval for 

 in combination with daratumumab, hyaluronidase-fihj, and dexamethasone for relapsed/refractory multiple myeloma, based on EXCALIBER-RRMM data showing a 41% MRD-negative complete response rate versus 21% for the comparator arm; the drug carries boxed warnings and restricted REMS distribution given embryo-fetal toxicity risk.

Neurology and infectious disease also saw approvals for new drugs. The FDA approved 

, the first orex in receptor agonist for narcolepsy type 1, which the Center for Drug Evaluation and Research (CDER) Psychiatry Division Director Tiffany Farchione described as “the first medicine that impacts the underlying biology of the disease.”

, a tau PET imaging agent that Massachusetts General Hospital's Keith Johnson said is “essential for increasing our understanding of potential disease impacts” in Alzheimer's evaluation, though the approval excludes non-Alzheimer's tauopathies.

, the first messenger RNA-based flu vaccine, for adults 50 and older, contingent on a confirmatory trial in the oldest cohort, after a 40,000-plus-participant trial showed roughly 27% higher effectiveness than a standard-dose comparator.

 from birth through four weeks based on the IMPAACT 2023 study,

 as the first oral therapy for adult dermatomyositis, which FDA's Nikolay Nikolov said is “giving patients and their healthcare providers an approved oral therapy.”

 new drug application for pediatric Tourette syndrome was accepted with priority review, targeting an action date in early 2027; EVP Eric Hughes called it potentially “the first novel mechanism of action in more than 50 years” for the condition.

The FDA also moved on several policy fronts. A 

draft revision on choosing between an abbreviated new drug application and a 505(b)(2) application

 is open for comment through October 19, updating 2019 guidance on the same question.

draft guidance on container closure systems

 for human drugs and biologics, including combination product components is open for comment through October 13.

"What stands out in the draft guidance is the emphasis on understanding container closure integrity as part of the overall manufacturing process rather than as a standalone compliance exercise. For sterile drugs and biologics, especially in high-value injectable formats, manufacturers need reliable ways to detect defects that may compromise package integrity before products reach patients. Technologies such as automated vision inspection and deterministic CCIT methods can provide a deeper understanding of process performance, helping manufacturers move from reactive testing toward real process control. That's where we see the industry heading, and the guidance aligns well with that direction," Daniele Ansaldi, Technical Manager, Inspection Machines for Antares Vision Group, told 

And Deborah Smook, VP of Marketing & Business Development for TurboFil Packaging Machines LLC, provided her take on the guidance, telling 

: “FDA’s new draft guidance updates container closure recommendations that have been in place for more than 25 years, reflecting advances in drug-delivery systems, combination products, materials science, and testing. Of particular relevance to equipment manufacturers such as TurboFil, the updated guidance places more explicit emphasis on how manufacturing and assembly processes can affect container closure integrity and device performance, including the control and validation of parameters such as capping, stoppering, and other closure operations. We believe this reinforces the value of involving filling and assembly equipment suppliers early in product development, when component specifications, tolerances and critical process parameters can be addressed before the manufacturing process is finalized.”

potency assessment standards for active immunotherapy products

, supplementing 2023 guidance on cellular and gene therapies, with comments due November 18, 2026.

 tied to injectable glutathione made with dietary-supplement-grade material from a single lot, prompting recalls at two Texas pharmacies and a reminder that supplement-grade ingredients aren’t fit for injectable use.

In a move tied to the administration's broader pricing push, the FDA 

released 55 new or revised product-specific guidances

 to support generic-drug development for more than 30 products that currently lack generic competition.

guidance on therapeutic equivalence evaluations and Orange Book TE codes

, closing out a draft that had been open since 2022.

Manufacturing Compliance: FDA-Issued Warning Letters

FDA enforcement activity was active throughout August. 

 was cited for distributing APIs without adequate process validation, incomplete batch records, and missing stability testing.

 drew scrutiny for continuing sterile manufacturing after repeated media-fill failures and inadequate visual inspection and has since initiated a voluntary recall.

 failed, according to the FDA, to test incoming components and did not investigate out-of-limit microbial results.

 faced findings on aseptic-processing design and environmental monitoring, with the FDA noting similar deficiencies across multiple company sites.

 was cited for incomplete laboratory records and a pattern of retesting until passing results were obtained without documented justification.

 was flagged for inadequate quality-unit oversight, improper product segregation, and gaps in distribution traceability.

Together, the letters underscore the FDA’s continued focus on aseptic technique, data integrity, and quality-unit authority as recurring inspection themes.

In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) approved Deciphera's 

 for tenosynovial giant cell tumor, with Executive Director Julian Beach noting it “provides a new treatment option for patients with TGCT.”

, with Chief Safety Officer Alison Cave stating plainly that “there is no evidence that vaccines cause autism in children.”

staked out its regulatory position on microbiome-based medicinal products

, confirming they fall under existing UK medicines law—an area Beach called “one of the most interesting and fast-moving areas in medicine today.”

the first country in Europe to authorize Eli Lilly's oral orforglipron (Foundayo)

 for weight management and type 2 diabetes,

In August 2026, Heidi Overton was nominated for FDA commission, and a wave of oncology and neuro drugs were approved.

Featured Content

Pharma's AI ROI Problem Isn't a Tech Problem but a Qualification Problem

Manufacturing Intelligence: Sizing Up Pharma's Biggest AI Deals, Part Two

Regulatory Actions Impacting Biologics

Regulatory Roundup—July 2026

Pharma Fundamentals: An Introduction to Hold Times in Biopharmaceuticals

PharmTech Weekly Roundup—July 17, 2026

Regulatory Actions Impacting Biologics

Drug Digest April 2026